Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study

Molecular Carcinogenesis

Volumn 51, Issue 12, 2012, Pages 952-962

  Pandey, Mitali ^a   Kaur, Parminder ^a   Shukla, Sanjeev ^a   Abbas, Ata ^a   Fu, Pingfu ^a,b   Gupta, Sanjay ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Apigenin; Chromatin remodeling; Epigenetics; Histone modification; Prostate cancer

Indexed keywords

APIGENIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE H3; HISTONE H4; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; TRICHOSTATIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ACETYLATION; ANIMALS; APIGENIN; APOPTOSIS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA PRIMERS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; PLANTS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS;

MUS; MUS MUSCULUS;

EID: 84867745055     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20866     Document Type: Article

References (49)

1. Kanwal R, Gupta S. Epigenetics and cancer. J Appl Physiol 2010; 109: 598-605.
2. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
3. Tsai HC, Baylin SB. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res 2011; 21: 502-517.
4. Kim MK, Shin JM, Eun HC, Chung JH. The role of p300 histone acetyltransferase in UV-induced histone modifications and MMP-1 gene transcription. PLoS One 2009; 4: e4864.
5. Lee KK, Workman JL. Histone acetyltransferase complexes: One size doesn't fit all. Nat Rev Mol Cell Biol 2007; 8: 284-295.
6. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138: 1019-1031.
7. Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics. 2008; 3: 300-309.
8. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1: 19-25.
9. Nakagawa M, Oda Y, Eguchi T, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769-774.
10. Song Y, Shiota M, Tamiya S, Kuroiwa K, Naito S, Tsuneyoshi M. The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. Histopathology 2011; 58: 773-780.
11. Weichert W, Röske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98: 604-610.
12. Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E, Castronovo V. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem 2004; 48: 273-290.
13. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001; 287: 705-713.
14. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59: 177-189.
15. Zupkovitz G, Grausenburger R, Brunmeir R, et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol 2010; 30: 1171-1181.
16. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241-1246.
17. Neuhouser ML. Dietary flavonoids and cancer risk: Evidence from human population studies. Nutr Cancer 2004; 50: 1-7.
18. Lewis JE, Soler-Vilá H, Clark PE, Kresty LA, Allen GO, Hu JJ. Intake of plant foods and associated nutrients in prostate cancer risk. Nutr Cancer 2009; 61: 216-224.
19. Birt DF, Pelling JC, Nair S, Lepley D. Diet intervention for modifying cancer risk. Prog Clin Biol Res 1996; 395: 223-234.
20. Shukla S, Gupta S. Apigenin: A promising molecule for cancer prevention. Pharm Res 2010; 27: 962-978.
21. Xu L, Zhang L, Bertucci AM, Pope RM, Datta SK. Apigenin, a dietary flavonoid, sensitizes human T cells for activation-induced cell death by inhibiting PKB/Akt and NF-kappaB activation pathway. Immunol Lett 2008; 121: 74-83.
22. Shukla S, Gupta S. Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study. Mol Carcinog 2009; 48: 243-252.
23. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 2005; 19: 342-353.
24. Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog 2008; 47: 686-700.
25. Shukla S, MacLennan GT, Flask CA, et al. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 2007; 67: 6925-6935.
26. Shukla S, Gupta S. Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic Biol Med 2008; 44: 1833-1845.
27. Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 2007; 6: 1102-1114.
28. Franzen CA, Amargo E, Todorović V, et al. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism. Cancer Prev Res 2009; 2: 830-841.
29. Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 2002; 21: 3727-3738.
30. Lu HF, Chie YJ, Yang MS, et al. Apigenin induces caspase-dependent apoptosis in human lung cancer A549cells through Bax- and Bcl-2-triggered mitochondrial pathway. Int J Oncol 2010; 36: 1477-1484.
31. Hollman PC, Katan MB. Dietary flavonoids: Intake, health effects and bioavailability. Food Chem Toxicol 1999; 37: 937-942.
32. Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: Time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 2006; 27: 344-349.
33. Meeran SM, Ahmed A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenet 2010; 1: 101-116.
34. Kang MR, Kang JS, Han SB, et al. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem Pharmacol 2009; 78: 486-494.
35. Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol 2006; 13: 581-586.
36. Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004; 3: 779-788.
37. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-4642.
38. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. Int J Cancer 2004; 112: 171-178.
39. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188-193.
40. Krämer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003; 22: 3411-3420.
41. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 2009; 100: 758-763.
42. Ammanamanchi S, Brattain MG. Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J Biol Chem 2004; 279: 32620-32625.
43. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res 2004; 64: 5767-5774.
44. Wang LG, Liu XM, Fang Y, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008; 33: 375-380.
45. Li Y, Li X, Guo B. Chemopreventive agent 3, 3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res 2010; 70: 646-654.
46. Pandey M, Shukla S, Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer 2010; 126: 2520-2533.
47. Druesne N, Pagniez A, Mayeur C, et al. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 2004; 251: 227-236.
48. Gradolatto A, Basly JP, Berges R, et al. Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metab Dispos 2005; 33: 49-54.
49. Ross JA, Kasum CM. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002; 22: 19-34.